Celldex Therapeutics (CLDX) has an average broker rating of 1.89, which is interpreted as a Buy, as rated by 9 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Celldex Therapeutics (CLDX) : The highest level Celldex Therapeutics (CLDX) is projected to reach is $24 for the short term and the lowest estimate is at $3. The consolidated price target from 8 rating analysts who initiate coverage on the stock is $8.75 and the possibility the share price can swing is $6.8.
For the current week, the company shares have a recommendation consensus of Buy. Celldex Therapeutics (NASDAQ:CLDX): The stock opened at $4.54 on Thursday but the bulls could not build on the opening and the stock topped out at $4.59 for the day. The stock traded down to $4.34 during the day, due to lack of any buying support eventually closed down at $4.36 with a loss of -3.11% for the day. The stock had closed at $4.50 on the previous day. The total traded volume was 2,655,909 shares.
In a related news, Catlin Avery W, officer (Sr. VP & CFO) of Celldex Therapeutics, Inc., unloaded 25,000 shares at an average price of $18 on November 23, 2015. The total amount of the transaction was worth $450,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.